Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 99.02 Billion KRW | -27.86% |
| 2022 | 137.27 Billion KRW | 8.75% |
| 2021 | 126.23 Billion KRW | 4.36% |
| 2020 | 120.96 Billion KRW | 32.39% |
| 2019 | 91.36 Billion KRW | 22.98% |
| 2018 | 74.29 Billion KRW | 2.49% |
| 2017 | 72.48 Billion KRW | 0.06% |
| 2016 | 72.44 Billion KRW | 14.67% |
| 2015 | 63.17 Billion KRW | 12.75% |
| 2014 | 56.02 Billion KRW | 10.4% |
| 2013 | 50.75 Billion KRW | 25.99% |
| 2012 | 40.28 Billion KRW | -15.57% |
| 2011 | 47.7 Billion KRW | -7.52% |
| 2010 | 51.58 Billion KRW | 23.4% |
| 2009 | 41.8 Billion KRW | 23.54% |
| 2008 | 33.84 Billion KRW | 43.09% |
| 2007 | 23.65 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 27.81 Billion KRW | 6.7% |
| 2024 Q1 | 26.07 Billion KRW | 40.66% |
| 2023 Q4 | 18.53 Billion KRW | -23.51% |
| 2023 FY | 99.02 Billion KRW | -27.86% |
| 2023 Q1 | 27.38 Billion KRW | -1.26% |
| 2023 Q2 | 30.76 Billion KRW | 12.34% |
| 2023 Q3 | 24.23 Billion KRW | -21.24% |
| 2022 Q2 | 37.23 Billion KRW | 0.33% |
| 2022 Q3 | 35.18 Billion KRW | -5.52% |
| 2022 Q4 | 27.73 Billion KRW | -21.17% |
| 2022 Q1 | 37.11 Billion KRW | 46.53% |
| 2022 FY | 137.27 Billion KRW | 8.75% |
| 2021 Q3 | 28.83 Billion KRW | -22.13% |
| 2021 Q4 | 25.33 Billion KRW | -12.15% |
| 2021 FY | 126.23 Billion KRW | 4.36% |
| 2021 Q1 | 35.03 Billion KRW | 27.32% |
| 2021 Q2 | 37.03 Billion KRW | 5.69% |
| 2020 Q1 | 29.87 Billion KRW | 36.67% |
| 2020 FY | 120.96 Billion KRW | 32.39% |
| 2020 Q4 | 27.51 Billion KRW | -11.1% |
| 2020 Q3 | 30.95 Billion KRW | -5.23% |
| 2020 Q2 | 32.66 Billion KRW | 9.34% |
| 2019 FY | 91.36 Billion KRW | 22.98% |
| 2019 Q4 | 21.86 Billion KRW | -3.39% |
| 2019 Q3 | 22.62 Billion KRW | -6.39% |
| 2019 Q1 | 22.71 Billion KRW | 42.4% |
| 2019 Q2 | 24.17 Billion KRW | 6.43% |
| 2018 Q2 | 21.53 Billion KRW | 14.65% |
| 2018 Q3 | 18.03 Billion KRW | -16.25% |
| 2018 Q4 | 15.94 Billion KRW | -11.56% |
| 2018 FY | 74.29 Billion KRW | 2.49% |
| 2018 Q1 | 18.78 Billion KRW | 13.03% |
| 2017 FY | 72.48 Billion KRW | 0.06% |
| 2017 Q4 | 16.61 Billion KRW | -7.76% |
| 2017 Q3 | 18.01 Billion KRW | -7.38% |
| 2017 Q2 | 19.45 Billion KRW | 5.68% |
| 2017 Q1 | 18.4 Billion KRW | 9.01% |
| 2016 FY | 72.44 Billion KRW | 14.67% |
| 2016 Q4 | 16.88 Billion KRW | -9.08% |
| 2016 Q3 | 18.56 Billion KRW | -8.44% |
| 2016 Q2 | 20.28 Billion KRW | 21.36% |
| 2016 Q1 | 16.71 Billion KRW | 14.09% |
| 2015 Q3 | 15.59 Billion KRW | -11.5% |
| 2015 FY | 63.17 Billion KRW | 12.75% |
| 2015 Q1 | 15.31 Billion KRW | 24.24% |
| 2015 Q2 | 17.61 Billion KRW | 15.02% |
| 2015 Q4 | 14.64 Billion KRW | -6.06% |
| 2014 FY | 56.02 Billion KRW | 10.4% |
| 2014 Q4 | 12.32 Billion KRW | -15.94% |
| 2014 Q3 | 14.66 Billion KRW | -6.02% |
| 2014 Q2 | 15.6 Billion KRW | 16.28% |
| 2014 Q1 | 13.42 Billion KRW | 16.22% |
| 2013 Q1 | 11.62 Billion KRW | 32.51% |
| 2013 Q2 | 15.21 Billion KRW | 30.9% |
| 2013 FY | 50.75 Billion KRW | 25.99% |
| 2013 Q4 | 11.54 Billion KRW | -6.58% |
| 2013 Q3 | 12.36 Billion KRW | -18.76% |
| 2012 Q3 | 8.91 Billion KRW | -20.1% |
| 2012 Q2 | 11.16 Billion KRW | 79.86% |
| 2012 Q4 | 8.77 Billion KRW | -1.64% |
| 2012 FY | 40.28 Billion KRW | -15.57% |
| 2012 Q1 | 6.2 Billion KRW | 0.0% |
| 2011 Q2 | 9.64 Billion KRW | 15.82% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 47.7 Billion KRW | -7.52% |
| 2011 Q1 | 8.33 Billion KRW | 0.0% |
| 2011 Q3 | 7.56 Billion KRW | -21.55% |
| 2010 Q2 | 9.29 Billion KRW | 49.33% |
| 2010 FY | 51.58 Billion KRW | 23.4% |
| 2010 Q1 | 6.22 Billion KRW | 0.0% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q3 | 7.53 Billion KRW | -18.92% |
| 2009 Q2 | 8.84 Billion KRW | 15.02% |
| 2009 Q1 | 7.68 Billion KRW | 0.0% |
| 2009 FY | 41.8 Billion KRW | 23.54% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q3 | 6.78 Billion KRW | -23.28% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 33.84 Billion KRW | 43.09% |
| 2008 Q2 | 7.4 Billion KRW | 41.11% |
| 2008 Q3 | 6.4 Billion KRW | -13.48% |
| 2008 Q1 | 5.24 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 23.65 Billion KRW | 0.0% |
| 2007 Q3 | 5.4 Billion KRW | -14.2% |
| 2007 Q1 | 4.03 Billion KRW | 0.0% |
| 2007 Q2 | 6.29 Billion KRW | 55.96% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -112.938% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 72.803% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 50.209% |
| HANDOK Inc. | 151.36 Billion KRW | 34.578% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -47.308% |
| Yuhan Corporation | 564.5 Billion KRW | 82.458% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 69.266% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -317.008% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 88.153% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -31.967% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 50.228% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -143.611% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -4.773% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 29.696% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -112.938% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -185.251% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -28.911% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 922.101% |
| JW Holdings Corporation | 446.15 Billion KRW | 77.804% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 52.285% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 84.889% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.499% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -25.957% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -31.618% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -37.135% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 46.127% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -112.938% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 66.445% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 85.47% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.499% |
| Yuhan Corporation | 564.5 Billion KRW | 82.458% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 50.933% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -39.595% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 70.499% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 32.123% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 42.92% |
| CKD Bio Corp. | 5.01 Billion KRW | -1876.469% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 61.049% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 46.217% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -0.919% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -25.957% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 73.344% |
| Boryung Corporation | 333.26 Billion KRW | 70.286% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -97.874% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 50.228% |
| JW Lifescience Corporation | 51.32 Billion KRW | -92.941% |